Is ALKS a buy in 2026?

No — Framler currently rates it bearish based on the multi-factor Framler engine score of 29/100. Top drivers: Defensive / negative MD&A language flagged; Sector in favour — rotation tailwind; Heavy short interest with downward momentum. Framler combines momentum, quality, value, options flow, insider activity and HMM regime detection to score US and international equities daily. This is statistical research, not investment advice.

Is the read supported by multiple factors, or just one?

The page lists how many of the 13 factors point bullish, bearish, or neutral for ALKS. Multi-factor alignment indicates stronger conviction; a single-factor signal warrants caution.

Is the uncertainty wide or narrow?

Each ticker shows a 90% Mondrian conformal range (Vovk-Shafer 2005) around the score — the band where the ticker's realised 30-day return rank, against the rest of the universe, is expected to land. It is not a price target. The width comes from the calibration bin, not from how much the factors agree.

Is the read confirmed by sector and regime?

Sector score, BOCPD regime classification (risk-on / transition / risk-off), and the active confluence pattern all appear on the page. Aligned context tightens conviction; misaligned context widens the interval and softens the verdict.

What would invalidate this read?

Factor flips week-over-week, a regime shift, fresh earnings, or insider sells are the main invalidators. Scores update daily; the 30-day score sparkline above the factor breakdown surfaces trend drift in real time.

Healthcare · NASDAQ

Calibration 4/4:1d7d30d90d

ALKS STOCK · Alkermes plc BearishMulti-factor aligned

$48.02-4.30%

~1-month outlook, not a day-trade. The score updates daily as the data changes — re-check weekly rather than reacting to a single day's move.

Sector calibration · noisy

Engine accuracy in Healthcare has been close to zero on recent rolling windows. Treat the composite as informational. Lean on Confluence patterns, Insider clustering, and Options flow — sub-signals that retain edge in narrative-driven cohorts.

AgreementMODERATE ALIGNMENT

Some factor streams agree, others diverge.

90% interval: [5–79]Top driver: NLP Tone

PATTERN HISTORY · 14Dhit rate 62.1%mean ret +2.34%n=612Measured across every ticker that fired this setup — not this stock's own history.

Bottom quartile — weak factor setup for this regime🔒 Sign in for number

Why ALKS scores 29

Defensive / negative MD&A language flagged
Sector in favour — rotation tailwind
Heavy short interest with downward momentum

Full report — sign in to unlock

🧬 Phase 3 / FDA catalyst

ALKS has an active Phase 3 clinical trial — NCT05303064. Framler models the failure probability for ALKS from ClinicalTrials.gov data — the figure is shown after you sign in.

🧬 Biotech intelligence

Bayesian Phase-3 trial failure probability vs the disease base rate, an estimated FDA decision window, patent-cliff timing, and comparable historical trials — the biotech layer for ALKS.

🔒 Sign up to unlock →

🔒 Forward-Return Projection

Expected returns over 1 / 7 / 30 / 90 days with 90% confidence intervals, regime amplifier, pattern multiplier, copula tail-dependence — composed into one Bayesian distribution.

🔒 Full Factor Breakdown

Per-factor 0-100 scores across quality, value, momentum, PEAD, accruals, insider flow, NLP tone, options flow, short interest, sector momentum, factor interaction — plus the score waterfall.

🔒 Confluence Patterns

Active multi-factor patterns (QUALITY COMPOUNDER, VALUE TRAP, SHORT SQUEEZE, OVEREXTENDED, etc.) with academic basis and pattern delta against the raw composite.

🔒 Plain-English Explanation & Scenarios

Plain-English read of what the engine sees on this ticker today + what-if scenarios (price ±N%, regime flip, shock) replayed through the deterministic engine. No AI in the scoring path.

Unlock the full ALKS report

Free during early access · no credit card · 1,000+ stocks tracked daily

Were we right on ALKS? — 72 graded days

WE MADE A CALL ON 47 OF 72 DAYS — RIGHT 24 · WRONG 23